Jose Ignacio López

Dr. Jose Ignacio López

Head, Department of Pathology, Cruces University Hospital
+1
orcid

Research Focus & Metrics

Academic Career Length

40Years (1987-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2018 in Cell
Verified
Journal Article
Open access
STSamra Turajlic
Samra Turajlic
HXHang Xu
Hang Xu
KLKevin Litchfield
Kevin Litchfield
ARAndrew Rowan
Andrew Rowan
TCTim Chambers
Tim Chambers
CSCharles Swanton
Charles Swanton
Clear-cell renal cell carcinoma (ccRCC) exhibits a broad range of metastatic phenotypes that have not been systematically studied to date. Here, we analyzed 575 primary and 335 metastatic biopsies across 100 patients with metastatic ccRCC, including two cases sampledat post-mortem. Metastatic competence was afforded by chromosome complexity, and we identify 9p loss as a highly selected event driving metastasis and ccRCC-related mortality (p = 0.0014). Distinct patterns of metastatic dissemination were observed, including rapid progression to multiple tissue sites seeded by primary tumors of monoclonal structure. By contrast, we observed attenuated progression in cases characterized by high primary tumor heterogeneity, with metastatic competence acquired gradually and initial progression to solitary metastasis. Finally, we observed early divergence of primitive ancestral clones and protracted latency of up to two decades as a feature of pancreatic metastases.

1 April 2018 in Cell
Verified
Journal Article
Open access
STSamra Turajlic
Samra Turajlic
HXHang Xu
Hang Xu
KLKevin Litchfield
Kevin Litchfield
ARAndrew Rowan
Andrew Rowan
SHStuart Horswell
Stuart Horswell
CSCharles Swanton
Charles Swanton
The evolutionary features of clear-cell renal cell carcinoma (ccRCC) have not been systematically studied to date. We analyzed 1,206 primary tumor regions from 101 patients recruited into the multi-center prospective study, TRACERx Renal. We observe up to 30 driver events per tumor and show that subclonal diversification is associated with known prognostic parameters. By resolving the patterns of driver event ordering, co-occurrence, and mutual exclusivity at clone level, we show the deterministic nature of clonal evolution. ccRCC can be grouped into seven evolutionary subtypes, ranging from tumors characterized by early fixation of multiple mutational and copy number drivers and rapid metastases to highly branched tumors with >10 subclonal drivers and extensive parallel evolution associated with attenuated progression. We identify genetic diversity and chromosomal complexity as determinants of patient outcome. Our insights reconcile the variable clinical behavior of ccRCC and suggest evolutionary potential as a biomarker for both intervention and surveillance.

1 April 2018 in Cancer Cell
Verified
Journal Article
Open access
FVFrederick Arce Vargas
Frederick Arce Vargas
AFAndrew J.S. Furness
Andrew J.S. Furness
KLKevin Litchfield
Kevin Litchfield
KJKroopa Joshi
Kroopa Joshi
RRRachel Rosenthal
Rachel Rosenthal
SQSergio A. Quezada
Sergio A. Quezada
With the use of a mouse model expressing human Fc-gamma receptors (FcγRs), we demonstrated that antibodies with isotypes equivalent to ipilimumab and tremelimumab mediate intra-tumoral regulatory T (Treg) cell depletion in vivo, increasing the CD8+ to Treg cell ratio and promoting tumor rejection. Antibodies with improved FcγR binding profiles drove superior anti-tumor responses and survival. In patients with advanced melanoma, response to ipilimumab was associated with the CD16a-V158F high affinity polymorphism. Such activity only appeared relevant in the context of inflamed tumors, explaining the modest response rates observed in the clinical setting. Our data suggest that the activity of anti-CTLA-4 in inflamed tumors may be improved through enhancement of FcγR binding, whereas poorly infiltrated tumors will likely require combination approaches.

1 April 2018 in Cell
Verified
Journal Article
Open access
TMThomas J. Mitchell
Thomas J. Mitchell
STSamra Turajlic
Samra Turajlic
ARAndrew Rowan
Andrew Rowan
DNDavid Nicol
David Nicol
JFJames H.R. Farmery
James H.R. Farmery
PCPeter J. Campbell
Peter J. Campbell
Clear cell renal cell carcinoma (ccRCC) is characterized by near-universal loss of the short arm of chromosome 3, deleting several tumor suppressor genes. We analyzed whole genomes from 95 biopsies across 33 patients with clear cell renal cell carcinoma. We find hotspots of point mutations in the 5' UTR of TERT, targeting a MYC-MAX-MAD1 repressor associated with telomere lengthening. The most common structural abnormality generates simultaneous 3p loss and 5q gain (36% patients), typically through chromothripsis. This event occurs in childhood or adolescence, generally as the initiating event that precedes emergence of the tumor's most recent common ancestor by years to decades. Similar genomic changes drive inherited ccRCC. Modeling differences in age incidence between inherited and sporadic cancers suggests that the number of cells with 3p loss capable of initiating sporadic tumors is no more than a few hundred. Early development of ccRCC follows well-defined evolutionary trajectories, offering opportunity for early intervention.

1 November 2021 in Cancer Cell
Verified
Journal Article
Open access
LALewis Au
Lewis Au
EHEmine Hatipoglu
Emine Hatipoglu
MMMarc Robert de Massy
Marc Robert de Massy
KLKevin Litchfield
Kevin Litchfield
GBGordon Beattie
Gordon Beattie
HVHema Verma
Hema Verma
ADAPTeR is a prospective, phase II study of nivolumab (anti-PD-1) in 15 treatment-naive patients (115 multiregion tumor samples) with metastatic clear cell renal cell carcinoma (ccRCC) aiming to understand the mechanism underpinning therapeutic response. Genomic analyses show no correlation between tumor molecular features and response, whereas ccRCC-specific human endogenous retrovirus expression indirectly correlates with clinical response. T cell receptor (TCR) analysis reveals a significantly higher number of expanded TCR clones pre-treatment in responders suggesting pre-existing immunity. Maintenance of highly similar clusters of TCRs post-treatment predict response, suggesting ongoing antigen engagement and survival of families of T cells likely recognizing the same antigens. In responders, nivolumab-bound CD8+ T cells are expanded and express GZMK/B. Our data suggest nivolumab drives both maintenance and replacement of previously expanded T cell clones, but only maintenance correlates with response. We hypothesize that maintenance and boosting of a pre-existing response is a key element of anti-PD-1 mode of action.

4 March 2021 in Laboratory Investigation
Verified
Journal Article
Closed access
PDF file
Kiril TrpkovKiril Trpkov
Kiril Trpkov
OHOndrej Hes
Ondrej Hes
SWSean Williamson
Sean Williamson
AAAdebowale J. Adeniran
Adebowale J. Adeniran
Abbas AgaimyAbbas Agaimy
Abbas Agaimy
AGAnthony J. Gill
Anthony J. Gill